adimin

Cabaletta Bio Says FDA Grants Orphan Drug Designation To CABA-201 To Treat Systemic Sclerosis

Biotechnology company Cabaletta Bio, Inc. (CABA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, for the treatment of systemic sclerosis (SSc). CABA-201 is in development as a potential treatment for autoimmune diseases driven by B cells. The...

Read More

Australian Market Marginally Higher

Extending the slight gains in the previous session, the Australian stock market is marginally higher in choppy trading on Tuesday, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is staying just below the 7,700 level, with gains across most sectors led by mining and energy stocks amid spiking commodity prices....

Read More

Indonesia Stock Market May End Losing Streak

The Indonesia stock market has finished lower in back-to-back sessions, slumping more than 30 points or 0.4 percent in that span. The Jakarta Composite Index now sits just above the 7,300-point plateau although it may find traction on Tuesday. The global forecast for the Asian markets is upbeat, with support expected from technology and oil...

Read More

Japanese Market Notably Lower

Giving up some of the strong gains in the previous session, the Japanese stock market is notably lower on Tuesday, with the Nikkei 225 falling below the 39,600 level, despite the broadly positive cues from Wall Street overnight, with losses in index heavyweights and technology stocks as investors braced for a BOJ policy shift when...

Read More